

Resource Summary Report

Generated by [RRID](#) on Aug 24, 2026

pBabe-Puro-BRAF-V600E

RRID:Addgene_15269

Type: Plasmid

Proper Citation

RRID:Addgene_15269

Plasmid Information

URL: <http://www.addgene.org/15269>

Proper Citation: RRID:Addgene_15269

Insert Name: BRAF

Organism: Homo sapiens

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:17574021](#)

Vector Backbone Description: Backbone Size:5100; Vector Backbone:pBabe-puro; Vector Types:Mammalian Expression, Retroviral; Bacterial Resistance:Ampicillin

Plasmid Name: pBabe-Puro-BRAF-V600E

Relevant Mutation: Valine 600 to Glutamate (mutation has been found in cancer patients, confers increased kinase activity, and is transforming)

Record Creation Time: 20220422T221835+0000

Record Last Update: 20260815T080728+0000

Ratings and Alerts

No rating or validation information has been found for pBabe-Puro-BRAF-V600E.

No alerts have been found for pBabe-Puro-BRAF-V600E.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Weatherdon L, et al. (2024) Reporter cell lines to screen for inhibitors or regulators of the KRAS-RAF-MEK1/2-ERK1/2 pathway. *The Biochemical journal*, 481(6), 405.

Wang C, et al. (2024) METTL3-mediated chromatin contacts promote stress granule phase separation through metabolic reprogramming during senescence. *Nature communications*, 15(1), 5410.

Chen JY, et al. (2023) Multi-range ERK responses shape the proliferative trajectory of single cells following oncogene induction. *Cell reports*, 42(3), 112252.

Ye Q, et al. (2023) Oncogenic BRAFV600E induces microglial proliferation through extracellular signal-regulated kinase and neuronal death through c-Jun N-terminal kinase. *Neural regeneration research*, 18(7), 1613.

Prieto-Garcia C, et al. (2022) USP28 enables oncogenic transformation of respiratory cells, and its inhibition potentiates molecular therapy targeting mutant EGFR, BRAF and PI3K. *Molecular oncology*, 16(17), 3082.

Schauffer D, et al. (2021) Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer. *NPJ precision oncology*, 5(1), 102.

Martin AM, et al. (2020) PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status. *Journal of neuropathology and experimental neurology*, 79(1), 74.

Li S, et al. (2019) Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. *Nature communications*, 10(1), 1693.

Wang X, et al. (2019) BRAFV600E-induced KRT19 expression in thyroid cancer promotes lymph node metastasis via EMT. *Oncology letters*, 18(1), 927.

Tago K, et al. (2019) Oncogenic Ras mutant causes the hyperactivation of NF- κ B via acceleration of its transcriptional activation. *Molecular oncology*, 13(11), 2493.

Kemps PG, et al. (2019) Apparent Lack of BRAFV600E Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8⁺ T Cells in Langerhans Cell Histiocytosis. *Frontiers in immunology*, 10, 3045.

Ng MY, et al. (2018) Characterisation of cellular effects of Burkholderia pseudomallei cycle inhibiting factor (Cif). *Biology open*, 7(7).

Liu R, et al. (2018) Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer. *Nature communications*, 9(1), 579.

Welsch ME, et al. (2017) Multivalent Small-Molecule Pan-RAS Inhibitors. *Cell*, 168(5), 878.

Ng MY, et al. (2017) Activation of MAPK/ERK signaling by Burkholderia pseudomallei cycle inhibiting factor (Cif). PloS one, 12(2), e0171464.

Xu YC, et al. (2017) Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3K?-selective Inhibitors in Breast Cancer. Theranostics, 7(4), 974.

Tachibana N, et al. (2016) Pten Regulates Retinal Amacrine Cell Number by Modulating Akt, Tgf?, and Erk Signaling. The Journal of neuroscience : the official journal of the Society for Neuroscience, 36(36), 9454.

Kawakami H, et al. (2016) Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. Molecular cancer therapeutics, 15(12), 3015.

Hafner M, et al. (2016) Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nature methods, 13(6), 521.

Lakiotaki E, et al. (2016) Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome. Scientific reports, 6, 21252.